| Macromolecular structure determination using X-rays, neutrons and electrons: recent developments in Phenix D Liebschner, PV Afonine, ML Baker, G Bunkóczi, VB Chen, TI Croll, ... Acta Crystallographica Section D: Structural Biology 75 (10), 861-877, 2019 | 5056 | 2019 |
| MolProbity: more and better reference data for improved all‐atom structure validation CJ Williams, JJ Headd, NW Moriarty, MG Prisant, LL Videau, LN Deis, ... Protein Science 27 (1), 293-315, 2018 | 3399 | 2018 |
| The crystal structure of Mtr4 reveals a novel arch domain required for rRNA processing RN Jackson, AA Klauer, BJ Hintze, H Robinson, A Van Hoof, SJ Johnson The EMBO journal 29 (13), 2205-2216, 2010 | 134 | 2010 |
| Molprobity's ultimate rotamer‐library distributions for model validation BJ Hintze, SM Lewis, JS Richardson, DC Richardson Proteins: Structure, Function, and Bioinformatics 84 (9), 1177-1189, 2016 | 122 | 2016 |
| New insights into Hoogsteen base pairs in DNA duplexes from a structure-based survey H Zhou, BJ Hintze, IJ Kimsey, B Sathyamoorthy, S Yang, JS Richardson, ... Nucleic acids research 43 (7), 3420-3433, 2015 | 87 | 2015 |
| Model validation: local diagnosis, correction and when to quit JS Richardson, CJ Williams, BJ Hintze, VB Chen, MG Prisant, LL Videau, ... Acta Crystallographica Section D: Structural Biology 74 (2), 132-142, 2018 | 39 | 2018 |
| Respiratory syncytial virus during the COVID-19 pandemic compared to historic levels: a retrospective cohort study of a health system N Movva, M Suh, H Reichert, B Hintze, MP Sendak, Z Wolf, S Carr, ... The Journal of infectious diseases 226 (Supplement_2), S175-S183, 2022 | 24 | 2022 |
| Comparison of annotation services for next-generation sequencing in a large-scale precision oncology program E Katsoulakis, JE Duffy, B Hintze, NL Spector, MJ Kelley JCO Precision Oncology 4, 212-221, 2020 | 23 | 2020 |
| Genomic analysis of metastatic solid tumors in veterans: findings from the VHA National Precision Oncology Program PJ Poonnen, JE Duffy, B Hintze, M Shukla, TS Brettin, NR Conrad, H Yoo, ... JCO Precision Oncology 3, 1-13, 2019 | 19 | 2019 |
| Cis-nonPro Peptides: Genuine Occurrences and their Functional Roles CJ Williams, LL Videau, DC Richardson, JS Richardson BioRxiv, 324517, 2018 | 17 | 2018 |
| Mismodeled purines: implicit alternates and hidden Hoogsteens BJ Hintze, JS Richardson, DC Richardson Acta Crystallographica Section D: Structural Biology 73 (10), 852-859, 2017 | 14 | 2017 |
| CaBLAM: identification and scoring of disguised secondary structure at low resolution CJ Williams, BJ Hintze, DC Richardson, JS Richardson Comp. Cryst. Newslett 4, 33-35, 2013 | 12 | 2013 |
| Barriers to prescribing targeted therapies for patients with NSCLC with highly actionable gene variants in the Veterans Affairs National Precision Oncology Program V Vashistha, J Armstrong, D Winski, PJ Poonnen, B Hintze, M Price, ... JCO oncology practice 17 (7), e1012-e1020, 2021 | 11 | 2021 |
| Chemoradiation treatment patterns among United States Veteran Health Administration patients with unresectable stage III non-small cell lung cancer A Hung, KM Lee, JA Lynch, Y Li, P Poonnen, OV Efimova, BJ Hintze, ... BMC cancer 21, 1-11, 2021 | 8 | 2021 |
| Medical oncologists’ perspectives of the veterans affairs national precision oncology program V Vashistha, PJ Poonnen, JL Snowdon, HG Skinner, V McCaffrey, ... Plos one 15 (7), e0235861, 2020 | 8 | 2020 |
| Implementation of precision oncology in the Veterans Health Administration (VHA). MJ Kelley, J Duffy, BJ Hintze, CD Williams, NL Spector Journal of Clinical Oncology 35 (15_suppl), 6507-6507, 2017 | 5 | 2017 |
| EGFR mutation testing and TKI treatment patterns among veterans with stage III and IV non-small cell lung cancer A Hung, KM Lee, PR Alba, Y Li, AZ Gao, BJ Hintze, OV Efimova, ... Cancer Treatment and Research Communications 27, 100327, 2021 | 3 | 2021 |
| ResDe: a new tool for visual definition of distance restraints for crystallographic refinement BJ Hintze, SJ Johnson Journal of Applied Crystallography 43 (6), 1540-1542, 2010 | 3 | 2010 |
| Barriers to prescribing targeted therapies for NSCLC patients with highly actionable gene variants in the VA National Precision Oncology Program. V Vashistha, J Armstrong, D Winski, M Price, BJ Hintze, P Poonnen, ... Journal of Clinical Oncology 38 (15_suppl), 2005-2005, 2020 | 2 | 2020 |
| The Veterans Health Administration Precision Oncology Program for Advanced Prostate Cancer Patients: Expanding tumor NGS opportunities to a broader patient population. A Sokolova, HH Cheng, BJ Hintze, MJ Kelley, NL Spector, J Duffy, ... Journal of Clinical Oncology 37 (7_suppl), 193-193, 2019 | 2 | 2019 |